HPV vaccination impact on a cervical cancer screening program: Methods of the FASTER-tlalpan study in Mexico

Jorge Salmerón, Leticia Torres-Ibarra, F. Xavier Bosch, Jack Cuzick, Attila Lörincz, Cosette M. Wheeler, Philip E. Castle, Claudia Robles, Eduardo Lazcano-Ponce

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Objective: To outline the design of a clinical trial to evaluate the impact of HPV vaccination as part of a hrHPV-based primary screening program to extend screening intervals. Materials and methods: A total of 18,000 women aged 25-45 years, attending the regular cervical cancer-screening program in primary health care services in Tlalpan, Mexico City, will be invited to the study. Eligible participants will be assigned to one of three comparison groups: 1) HPV16/18 vaccine and hrHPV-based screening; 2) HPV6/11/16/18 vaccine and hrHPV-based screening; 3) Control group who will receive only hrHPV-based screening. Strict surveillance of hrHPV persistent infection and occurrence of precancerous lesions will be conducted to estimate safety profiles at different screening intervals; participants will undergo diagnosis confirmation and treatment as necessary. Conclusion: The FASTER-Tlalpan Study will provide insights into new approaches of cervical cancer prevention programs. It will offer valuable information on potential benefits of combin HPVing HPV vaccination and hrHPV-based screening to safety extend screening intervals.

Original languageEnglish (US)
Pages (from-to)211-219
Number of pages9
JournalSalud Publica de Mexico
Issue number2
StatePublished - 2016


  • Cervical intraepithelial neoplasia
  • Hpv
  • Mass screening
  • Mexico
  • Vaccination

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health


Dive into the research topics of 'HPV vaccination impact on a cervical cancer screening program: Methods of the FASTER-tlalpan study in Mexico'. Together they form a unique fingerprint.

Cite this